[go: up one dir, main page]

DE60115422D1 - PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR - Google Patents

PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR

Info

Publication number
DE60115422D1
DE60115422D1 DE60115422T DE60115422T DE60115422D1 DE 60115422 D1 DE60115422 D1 DE 60115422D1 DE 60115422 T DE60115422 T DE 60115422T DE 60115422 T DE60115422 T DE 60115422T DE 60115422 D1 DE60115422 D1 DE 60115422D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
composition containing
factor viia
tfpi inhibitor
tfpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60115422T
Other languages
English (en)
Other versions
DE60115422T2 (de
Inventor
Marianne Kjalke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of DE60115422D1 publication Critical patent/DE60115422D1/de
Publication of DE60115422T2 publication Critical patent/DE60115422T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60115422T 2000-05-10 2001-05-10 PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR Expired - Fee Related DE60115422T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK200000771 2000-05-10
DK200000778 2000-05-10
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DKPA200000871 2000-06-06
DK200000871 2000-06-06
PCT/DK2001/000324 WO2001085199A1 (en) 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR

Publications (2)

Publication Number Publication Date
DE60115422D1 true DE60115422D1 (de) 2006-01-05
DE60115422T2 DE60115422T2 (de) 2006-08-17

Family

ID=27222387

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60112429T Expired - Lifetime DE60112429T2 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
DE60115422T Expired - Fee Related DE60115422T2 (de) 2000-05-10 2001-05-10 PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60112429T Expired - Lifetime DE60112429T2 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1593389A1 (de)
JP (2) JP2003532684A (de)
CN (1) CN1304049C (de)
AT (2) ATE311198T1 (de)
AU (3) AU2001258228B2 (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60112429T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2254414T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085198A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU8755001A (en) * 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
CA2420892A1 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
EP1337267B1 (de) * 2000-11-03 2007-04-25 ZymoGenetics, Inc. Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
ATE367824T1 (de) * 2000-11-10 2007-08-15 Zymogenetics Inc Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
WO2002062377A2 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
JP2004521129A (ja) * 2001-02-21 2004-07-15 ザイモジェネティクス，インコーポレイティド フォン・ヴィレブランド病の処理方法
US7115559B2 (en) * 2001-09-10 2006-10-03 Zymogenetics Inc. Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446147A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
EP1446148A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
CN101675991A (zh) * 2001-12-21 2010-03-24 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
KR101212025B1 (ko) 2002-06-21 2013-01-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2006515882A (ja) * 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
EP1641487B1 (de) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Flüssige zusammensetzungen von factor vii polypeptiden
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
EP2392655A3 (de) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Gerinnungsfaktor VII Polypeptide
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
WO2006021584A2 (en) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification of factor xiii polypeptides from biological materials
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
WO2006056575A1 (en) 2004-11-23 2006-06-01 Zymogenetics, Inc. Purification of recombinant human factor xiii
US20090130086A1 (en) * 2005-02-28 2009-05-21 Novo Nordisk Health Care Ag FXIII Variants with Improved Properties
WO2007014749A2 (en) * 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
EP2046371A2 (de) * 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Faktor-viia-analoga mit erhöhter aktivität zur behandlung von thrombozytopenie
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
KR101710471B1 (ko) 2008-04-21 2017-02-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 건조한 트랜스글루타미나제 조성물
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
ES2621809T3 (es) * 2010-03-19 2017-07-05 Baxalta GmbH Inhibidores de TFPI y procedimientos de uso
AU2011287360A1 (en) 2010-08-05 2013-02-21 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
CN109134614A (zh) 2012-03-21 2019-01-04 百深有限责任公司 Tfpi抑制剂及其使用方法
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP7444059B2 (ja) * 2018-07-25 2024-03-06 ソニーグループ株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
JPH0780783B2 (ja) * 1985-11-26 1995-08-30 ノボ ノルディスク アクティーゼルスカブ 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
CZ83194A3 (en) * 1991-10-11 1994-11-16 Novo Nordisk As Haemostatic preparation for inducing blood precipitation on a bleeding wound
AU3423493A (en) * 1991-12-31 1993-07-28 Zymogenetics Inc. Methods and compositions for reducing blood loss
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
JP2002514948A (ja) * 1996-02-20 2002-05-21 コーヒージョン・コーポレーション 組織シーラント組成物とその使用方法
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU2094199A (en) * 1997-12-23 1999-07-12 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
WO1999058699A2 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
WO2002062377A2 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
EP1446148A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure

Also Published As

Publication number Publication date
WO2001085198A1 (en) 2001-11-15
ES2247106T3 (es) 2006-03-01
JP2003532684A (ja) 2003-11-05
EP1282439A1 (de) 2003-02-12
HUP0301868A3 (en) 2006-11-28
CZ20023667A3 (cs) 2003-04-16
US20070280920A1 (en) 2007-12-06
AU5822801A (en) 2001-11-20
DE60112429T2 (de) 2006-06-01
DE60115422T2 (de) 2006-08-17
EP1282439B1 (de) 2005-11-30
EP1282438A1 (de) 2003-02-12
HUP0301868A2 (hu) 2003-08-28
EP1282438B1 (de) 2005-08-03
AU2001258228B2 (en) 2006-01-12
ATE300953T1 (de) 2005-08-15
ATE311198T1 (de) 2005-12-15
US20030092627A1 (en) 2003-05-15
PL365042A1 (en) 2004-12-27
NO20025355L (no) 2003-01-09
IL152554A0 (en) 2003-05-29
CN1304049C (zh) 2007-03-14
WO2001085199A1 (en) 2001-11-15
JP2004505016A (ja) 2004-02-19
CA2406583A1 (en) 2001-11-15
ES2254414T3 (es) 2006-06-16
NO20025355D0 (no) 2002-11-08
CN1429117A (zh) 2003-07-09
DK1282438T3 (da) 2005-11-14
DE60112429D1 (de) 2005-09-08
AU2001258230A1 (en) 2001-11-20
US20060199766A1 (en) 2006-09-07
EP1593389A1 (de) 2005-11-09
BR0110659A (pt) 2003-02-11

Similar Documents

Publication Publication Date Title
ATE311198T1 (de) Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor
SE0102315D0 (sv) Compounds
ATE380054T1 (de) Topisches mittel zur dermatologischen verwendung enthaltend 4-hydroxyphenyl-alpha-d-glucopyranosid
FI961863A0 (fi) Farmaseuttinen seos, joka sisältää ACE-inhibiittorin ramipriilin ja dihydropyridiiniyhdisteen
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
ATE331500T1 (de) Synergistische orale zusammensetzung gegen zahnbelag und gingivitis
DK0609606T3 (de)
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ATE302746T1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
ZA200108130B (en) Treatment of pulmonary hypertension.
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
BR8000753U (pt) Balão de inflar para decoração e folguedos
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee